Cell Death Dis:lncRNA DOCK9-AS2 promotes the development of thyroid papyrotic cancer.

Thyroid papyroid cancer (PTC) accounts for about 80% of all cases of thyroid cancer (TC).
, the treatment effect of PTC is generally satisfactory, and more than 95% of PTC patients can survive more than 5 years after treatment.
, about 15% of PTC cases still show invasiveness and poor prognosm.
PTC diagnosis and targeted treatment strategies still need to be improved.
current studies confirm that long non-coded RNA (lncRNA) can mediate cell-to-cell communication in tumor micro-environments.
DOCK9-AS2 is an expression level increase of DOCK9-AS2 in thyroid cancer samples shown in the database of exosome lncRNA, GEPIA and circlncRNAnet, but no studies have reported the function and regulation mechanism of DOCK9-AS2 in PTC.
the study analyzed lncRNA of difference expression in PTC through a bioinsynomic database, the researchers found that DOCK9-AS2 showed elevated expression in PTC and increased levels in plasma exosomes in PTC patients.
of the study showed that knocking down DOCK9-AS2 reduced the proliferation, migration, invasion, endocystic-interstational transformation (EMT) and stem cell properties of PTC cells.
further discovered that PTC tumor stem cells (PTC-CSC) can improve the dryness of PTC cells by presenting DOCK9-AS2 in the exosome.
mechanism studies have shown that DOCK9-AS2 interacts with SP1 and induces CTNNB1 (serial protein beta 1) transcription, and can act as a molecular sponge of miR-1972 to raise the expression level of CTNNB1, thereby activating the Wnt/beta-catenin signaling path in PTC cells.
In summary, the study revealed that lncRNA DOCK9-AS2 in PTC-CSC exosomes activates the Wnt/beta-catenin signaling pathline and promotes the development of thyroid papicular cancer, indicating that DOCK9-AS2 is a potential therapeutic target for PTC.
.